Given the FDA's tentative approval of YUTREPIA and favorable analyst ratings, I believe Liquidia (LQDA) has significant growth potential, promising substantial returns. Additionally, the removal of legal injunctions boosts prospects for final FDA approval soon, enhancing LQDA’s market position.